Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions

Abstract

Hepatocellular carcinoma (HCC) remains challenging to diagnose and manage, particularly at an early stage when curative treatment is most feasible. Artificial intelligence (AI) offers tools for integrating histopathology, radiology, laboratory testing, demographics, and electronic health records, while also creating opportunities for clinician-supervised AI-assisted procedural support. Deep learning applied to digitized pathology slides can support tumor subtype classification, grading, and microvascular invasion assessment. AI-driven imaging methods may support liver and lesion segmentation, small-nodule detection in cirrhotic livers, and non-invasive risk stratification when combined with radiomics and clinical variables. Emerging foundation models, large language models (LLMs), and agentic approaches may help structure evidence, summarize longitudinal records, and support guideline-aligned decision workflows. In AI-assisted treatment-support settings, robotic surgery, endoscopic platforms, and image-guided interventions should be viewed as environments for AI-assisted planning, navigation, documentation, and quality control rather than autonomous treatment systems. Most evidence remains retrospective, single-center, and vulnerable to domain shift. Other limitations include LLM/agentic reliability failures, limited interpretability, privacy constraints, computational burden, incomplete workflow integration, workforce readiness gaps, and uncertain clinical benefit. Future progress will require diverse multimodal datasets, prospective multicenter validation, explainable and lightweight algorithms, standardized data alignment, rigorous governance, patient-centered workflow implementation, staff training, and careful separation of technical feasibility from clinically meaningful outcomes. Responsibly deployed AI may support diagnostic consistency, workflow efficiency, and human–AI collaboration in HCC care.

Keywords

Artificial intelligence (AI) / Deep learning (DL) / Hepatocellular carcinoma (HCC) / Medical imaging / Large language model (LLM)

References

[1] Martinello M, Solomon SS, Terrault NA, Dore GJ. Hepatitis C. Lancet. 2023; 402:1085-1096. https://doi.org/10.1016/S0140—6736(23)01320—X.

[2] Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023; 79:516-537. https://doi.org/10.1016/j.jhep.2023.03.017.

[3] Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023; 20:864-884. https://doi.org/10.1038/s41571—023—00825—3.

[4] Nan Y, Xu X, Gao Y, et al. Consensus on the secondary prevention of primary liver cancer. Hepatol Int. 2021; 15:1289-1300. https://doi.org/10.1007/s12072—021—10259—7.

[5] Choi JH, Thung SN. Pathology and diagnostic approaches to well—differentiated hepatocellular lesions: a narrative review. J Yeungnam Med Sci. 2025; 42:5. https://doi.org/10.12701/jyms.2024.00766.

[6] Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med. 2023; 23:273-285. https://doi.org/10.1007/s10238—022—00799—z.

[7] Kiani A, Uyumazturk B, Rajpurkar P, et al. Impact of a deep learning assistant on the histopathologic classification of liver cancer. NPJ Digit Med. 2020; 3:23. https://doi.org/10.1038/s41746—020—0232—8.

[8] Ling Y, Ying S, Xu L, et al. Automatic volumetric diagnosis of hepatocellular carcinoma based on four—phase CT scans with minimum extra information. Front Oncol. 2022; 12:960178. https://doi.org/10.3389/fonc.2022.960178.

[9] Singh V, Chaganti S, Siebert M, et al. Deep learning—based identification of patients at increased risk of cancer using routine laboratory markers. Sci Rep. 2025; 15:12661. https://doi.org/10.1038/s41598—025—97331—6.

[10] Somvanshi S, Das S, Javed SA, Antariksa G, Hossain A. A Survey on Deep Tabular Learning. 2024. https://doi.org/10.48550/arXiv.2410.12034. ArXiv: 2410.12034.

[11] Vanguri RS, Luo J, Aukerman AT, et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD—(L)1 blockade in patients with non—small cell lung cancer. Nat Cancer. 2022; 3:1151-1164. https://doi.org/10.1038/s43018—022—00416—8.

[12] Low YS, Jackson ML, Hyde RJ, et al. Answering real—world clinical questions using large language model, retrieval—augmented generation, and agentic systems. Digit Health. 2025; 11:20552076251348850. https://doi.org/10.1177/20552076251348850.

[13] Zakka C, Shad R, Chaurasia A, et al. Almanac — Retrieval—Augmented language models for clinical medicine. NEJM AI. 2024; 1:10.1056/aioa2300068. https://doi.org/10.1056/aioa2300068.

[14] Xu X, Sankar R. Large language model agents for biomedicine: a comprehensive review of methods, evaluations, challenges, and future directions. Information (Switzerland). 2025; 16:894. https://doi.org/10.3390/info16100894.

[15] Vasey B, Lippert KAN, Khan DZ, et al. Intraoperative applications of artificial intelligence in robotic surgery: a scoping review of current development stages and levels of autonomy. Ann Surg. 2023; 278:896-903. https://doi.org/10.1097/SLA.0000000000005700.

[16] Knudsen JE, Ghaffar U, Ma R, Hung AJ. Clinical applications of artificial intelligence in robotic surgery. J Robot Surg. 2024; 18:102. https://doi.org/10.1007/s11701—024—01867—0.

[17] Schmidgall S, Opfermann JD, Kim JW, Krieger A. Will your next surgeon be a robot? Autonomy and AI in robotic surgery. Sci Robot. 2025; 10:eadt0187. https://doi.org/10.1126/scirobotics.adt0187.

[18] Yoon J, Oh K, Shin Y, Mazurowski M, Suk HI. Domain generalization for medical image analysis: a review. Proc IEEE. 2024; 112:1583-1609. https://doi.org/10.1109/JPROC.2024.3507831.

[19] Omar M, Sorin V, Collins JD, et al. Multi—model assurance analysis showing large language models are highly vulnerable to adversarial hallucination attacks during clinical decision support. Commun Med (Lond). 2025; 5:330. https://doi.org/10.1038/s43856—025—01021—3.

[20] Mukherjee S, Chinta A, Kim T, Sharma TA, Hakkani—Tur D. Premise—Augmented Reasoning Chains Improve Error Identification in Math Reasoning with LLMs. 2025. https://doi.org/10.48550/arXiv.2502.02362. arXiv:2502.02362.

[21] Li Y, El Habib Daho M, Conze PH, et al. A review of deep learning—based information fusion techniques for multimodal medical image classification. Comput Biol Med. 2024; 177:108635. https://doi.org/10.1016/j.compbiomed.2024.108635.

[22] Huang SC, Pareek A, Seyyedi S, Banerjee I, Lungren MP. Fusion of medical imaging and electronic health records using deep learning: a systematic review and implementation guidelines. NPJ Digit Med. 2020; 3:136. https://doi.org/10.1038/s41746—020—00341—z.

[23] Choi JH, Thung SN. Advances in histological and molecular classification of hepatocellular carcinoma. Biomedicines. 2023; 11:2582. https://doi.org/10.3390/biomedicines11092582.

[24] Jiang K, Al—Diffhala S, Centeno BA. Primary liver cancers—part 1: histopathology, differential diagnoses, and risk stratification. Cancer Control. 2018; 25:1073274817744625. https://doi.org/10.1177/1073274817744625.

[25] Schlageter M, Terracciano LM, D'Angelo S, Sorrentino P. Histopathology of hepatocellular carcinoma. World J Gastroenterol. 2014; 20:15955-15964. https://doi.org/10.3748/wjg.v20.i43.15955.

[26] Bellocq JP, Anger E, Camparo P, et al. Securising diagnosis in pathology in 2011. The diagnostic error: between rhetoric and reality [Securiser le diagnostic en anatomie et cytologie pathologiques en 2011. L'erreur diagnostique: entre discours et realite]. Ann Pathol. 2011; 31:S92-S94. https://doi.org/10.1016/j.annpat.2011.08.006.

[27] Dimitriou N, Arandjelovic O, Caie PD. Deep learning for whole slide image analysis: an overview. Front Med (Lausanne). 2019; 6:264. https://doi.org/10.3389/fmed.2019.00264.

[28] Nakatsuka T, Tateishi R, Sato M, et al. Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease. Hepatology. 2025; 81:976-989. https://doi.org/10.1097/HEP.0000000000000904.

[29] Liao Z, Tang C, Luo R, Gu X, Zhou J, Gao J. Current concepts of precancerous lesions of hepatocellular carcinoma: recent progress in diagnosis. Diagnostics (Basel). 2023; 13:1211. https://doi.org/10.3390/diagnostics13071211.

[30] Xie T, Huang A, Yan H, Ju X, Xiang L, Yuan J. Artificial intelligence: illuminating the depths of the tumor microenvironment. J Transl Med. 2024; 22:799. https://doi.org/10.1186/s12967—024—05609—6.

[31] Zhang X, Yu X, Liang W, et al. Deep learning—based accurate diagnosis and quantitative evaluation of microvascular invasion in hepatocellular carcinoma on whole—slide histopathology images. Cancer Med. 2024; 13:e7104. https://doi.org/10.1002/cam4.7104.

[32] Cheng N, Ren Y, Zhou J, et al. Deep learning—based classification of hepatocellular nodular lesions on whole—slide histopathologic images. Gastroenterology. 2022; 162:1948-1961 (e7). https://doi.org/10.1053/j.gastro.2022.02.025.

[33] Xia R, Boroujeni AM, Shea S, et al. Diagnosis of liver neoplasms by computational and statistical image analysis. Gastroenterol Res. 2019; 12:288-298. https://doi.org/10.14740/gr1210.

[34] Vasuri F, Malvi D, Bonora S, et al. From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. Histopathology. 2018; 72:414-422. https://doi.org/10.1111/his.13389.

[35] Li B, Huang L, Huang J, Li J. An update of immunohistochemistry in hepatocellular carcinoma. Diagnostics (Basel). 2025; 15:2144. https://doi.org/10.3390/diagnostics15172144.

[36] Zaidi S, Amdur R, Xiang X, et al. Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer. Genes Cancer. 2022; 13:9-20. https://doi.org/10.18632/genesandcancer.220.

[37] Ogunwobi OO, Harricharran T, Huaman J, et al. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol. 2019; 25:2279-2293. https://doi.org/10.3748/wjg.v25.i19.2279.

[38] Ding W, Zhang J, Jin Z, et al. Artificial intelligence—driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives. Discov Oncol. 2025; 16:1424. https://doi.org/10.1007/s12672—025—03254—z.

[39] Al—Obeidat F, Hafez W, Gador M, et al. Diagnostic performance of AI—based models versus physicians among patients with hepatocellular carcinoma: a systematic review and meta—analysis. Front Artif Intell. 2024; 7:1398205. https://doi.org/10.3389/frai.2024.1398205.

[40] Zhou Z, Cao S, Chen C, et al. A novel nomogram for the preoperative prediction of Edmondson—Steiner Grade III—IV in hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2023; 10:1399-1409. https://doi.org/10.2147/JHC.S417878.

[41] Deshpande A, Gupta D, Bhurane A, Meshram N, Singh S, Radeva P. Hybrid Deep Learning—based Strategy for the Hepatocellular Carcinoma Cancer Grade Classification of H&E Stained Liver Histopathology Images. 2024. https://doi.org/10.48550/arXiv.2412.03084. ArXiv:2412.03084.

[42] Liao H, Xiong T, Peng J, et al. Classification and prognosis prediction from histopathological images of hepatocellular carcinoma by a fully automated pipeline based on machine learning. Ann Surg Oncol. 2020; 27:2359-2369. https://doi.org/10.1245/s10434—019—08190—1.

[43] Wu S, Anand N, Guo Z, et al. Bridging immune evasion and vascular dynamics for novel therapeutic frontiers in hepatocellular carcinoma. Cancers (Basel). 2025; 17:1860. https://doi.org/10.3390/cancers17111860.

[44] Zheng J, Wang S, Xia L, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Targeted Ther. 2025; 10:35. https://doi.org/10.1038/s41392—024—02075—w.

[45] Dievernich A, Stegmaier J, Achenbach P, et al. A deep—learning—computed cancer score for the identification of human hepatocellular carcinoma area based on a six—colour multiplex immunofluorescence panel. Cells. 2023; 12:1074. https://doi.org/10.3390/cells12071074.

[46] Ghahremani P, Marino J, Hernandez—Prera J, et al. An AI—ready multiplex staining dataset for reproducible and accurate characterization of tumor immune microenvironment. Med Image Comput Comput Assist Interv. 2023; 14225:704-713. https://doi.org/10.1007/978—3—031—43987—2_68.

[47] Zhou L, Chen Y, Li Y, Wu C, Xue C, Wang X. Diagnostic value of radiomics in predicting Ki—67 and cytokeratin 19 expression in hepatocellular carcinoma: a systematic review and meta—analysis. Front Oncol. 2024; 13:1323534. https://doi.org/10.3389/fonc.2023.1323534.

[48] El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists' review. World J Gastroenterol. 2019; 25:1653-1665. https://doi.org/10.3748/wjg.v25.i14.1653.

[49] Loy LM, Low HM, Choi JY, Rhee H, Wong CF, Tan CH. Variant hepatocellular carcinoma subtypes according to the 2019 WHO classification: an imaging—focused review. AJR Am J Roentgenol. 2022; 219:212-223. https://doi.org/10.2214/AJR.21.26982.

[50] Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol. 2022; 35:23-32. https://doi.org/10.1038/s41379—021—00919—2.

[51] Franzen B, Auer G, Lewensohn R. Minimally invasive biopsy—based diagnostics in support of precision cancer medicine. Mol Oncol. 2024; 18:2612-2628. https://doi.org/10.1002/1878—0261.13640.

[52] Kusta O, Bearman M, Gorur R, Risør T, Brodersen JB, Hoeyer K. Speed, accuracy, and efficiency: the promises and practices of digitization in pathology. Soc Sci Med. 2024; 345:116650. https://doi.org/10.1016/j.socscimed.2024.116650.

[53] Haghshomar M, Rodrigues D, Kalyan A, Velichko Y, Borhani A. Leveraging radiomics and AI for precision diagnosis and prognostication of liver malignancies. Front Oncol. 2024; 14:1362737. https://doi.org/10.3389/fonc.2024.1362737.

[54] Tinglan L, Jun Q, Guihe Q, Weili S, Wentao Z. Liver segmentation network based on detail enhancement and multi—scale feature fusion. Sci Rep. 2025; 15:683. https://doi.org/10.1038/s41598—024—78917—y.

[55] Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922-1965. https://doi.org/10.1097/HEP.0000000000000466.

[56] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82:315-374. https://doi.org/10.1016/j.jhep.2024.08.028.

[57] An C, Rakhmonova G, Choi JY, Kim MJ. Liver imaging reporting and data system (LI—RADS) version 2014: understanding and application of the diagnostic algorithm. Clin Mol Hepatol. 2016; 22:296-307. https://doi.org/10.3350/cmh.2016.0028.

[58] Zhang WB, Hou SZ, Chen YL, et al. Deep learning for approaching hepatocellular carcinoma ultrasound screening dilemma: identification of α—fetoprotein—negative hepatocellular carcinoma from focal liver lesion found in high—risk patients. Front Oncol. 2022; 12:862297. https://doi.org/10.3389/fonc.2022.862297.

[59] Joo I, Kim SY, Kang TW, et al. Radiologic—pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid—enhanced MRI: a multicenter study. Radiology. 2020; 296:335-345. https://doi.org/10.1148/radiol.2020192275.

[60] Hu F, Zhang Y, Li M, et al. Preoperative prediction of microvascular invasion risk grades in hepatocellular carcinoma based on tumor and peritumor dual—region radiomics signatures. Front Oncol. 2022; 12:853336. https://doi.org/10.3389/fonc.2022.853336.

[61] Wu JY, Huang LM, Bai YN, et al. Imaging features of hepatocellular carcinoma with bile duct tumor thrombus: a multicenter study. Front Oncol. 2021; 11:723455. https://doi.org/10.3389/fonc.2021.723455.

[62] Wu G, Bajestani N, Pracha N, Chen C, Makary MS. Hepatocellular carcinoma surveillance strategies: major guidelines and screening advances. Cancers (Basel). 2024; 16:3933. https://doi.org/10.3390/cancers16233933.

[63] Fan R, Shi YR, Chen L, et al. Hepatocellular carcinoma risk stratification for cirrhosis patients: integrating radiomics and deep learning computed tomography signatures of the liver and spleen into a clinical model. J Clin Transl Hepatol. 2025; 13:743-753. https://doi.org/10.14218/JCTH.2025.00091.

[64] Li M, Zhang Z, Chen Z, et al. Interactive explainable deep learning model for hepatocellular carcinoma diagnosis at gadoxetic acid—enhanced MRI: a retrospective, multicenter, diagnostic study. Radiol Imaging Cancer. 2025; 7:e240332. https://doi.org/10.1148/rycan.240332.

[65] Siam A, Alsaify AR, Mohammad B, Biswas MR, Ali H, Shah Z. Multimodal deep learning for liver cancer applications: a scoping review. Front Artif Intell. 2023; 6:1247195. https://doi.org/10.3389/frai.2023.1247195.

[66] Al—Zoghby AM, Ebada AI, Saleh AS, Abdelhay M, Awad WA. A comprehensive review of multimodal deep learning for enhanced medical diagnostics. Comput Mater Contin. 2025; 84:4155-4193. https://doi.org/10.32604/cmc.2025.065571.

[67] Cellina M, Ce M, Khenkina N, et al. Artificial intelligence in the era of precision oncological imaging. Technol Cancer Res Treat. 2022; 21:15330338221141793. https://doi.org/10.1177/15330338221141793.

[68] Schurink NW, van Kranen SR, Roberti S, et al. Sources of variation in multicenter rectal MRI data and their effect on radiomics feature reproducibility. Eur Radiol. 2022; 32:1506-1516. https://doi.org/10.1007/s00330—021—08251—8.

[69] Li Q, Song H, Wei Z, et al. Densely connected U—Net with criss—cross attention for automatic liver tumor segmentation in CT images. IEEE ACM Trans Comput Biol Bioinf. 2023; 20:3399-3410. https://doi.org/10.1109/TCBB.2022.3198425.

[70] Jeon SK, Joo I, Park J, Kim JM, Park SJ, Yoon SH. Fully—automated multi—organ segmentation tool applicable to both non—contrast and post—contrast abdominal CT: deep learning algorithm developed using dual—energy CT images. Sci Rep. 2024; 14:4378. https://doi.org/10.1038/s41598—024—55137—y.

[71] Candita G, Rossi S, Cwiklinska K, et al. Imaging diagnosis of hepatocellular carcinoma: a state—of—the—art review. Diagnostics (Basel). 2023; 13:625. https://doi.org/10.3390/diagnostics13040625.

[72] Bilic P, Christ P, Li HB, et al. The liver tumor segmentation benchmark (LiTS). Med Image Anal. 2023; 84:102680. https://doi.org/10.1016/j.media.2022.102680.

[73] Zheng R, Wang L, Wang C, et al. Feasibility of automatic detection of small hepatocellular carcinoma (≤2 cm) in cirrhotic liver based on pattern matching and deep learning. Phys Med Biol. 2021; 66:10.1088/1361—6560/abf2f8. https://doi.org/10.1088/1361—6560/abf2f8.

[74] Li H, Liang B. Liver tumor computed tomography image segmentation based on an improved U—Net model. Appl Sci (Switzerland). 2023; 13:11283. https://doi.org/10.3390/app132011283.

[75] Kang M, Ting CM, Ting FF, Raphael Phan CW. Cafct—Net: a Cnn—Transformer hybrid network with contextual and attentional feature fusion for liver tumor segmentation. In: 2024 IEEE International Conference on Image Processing (ICIP). 2024:2970-2974. https://doi.org/10.1109/ICIP51287.2024.10647768.

[76] Saeed N, Ridzuan M, Majzoub RA, Yaqub M. Prompt—based tuning of transformer models for multi—center medical image segmentation of head and neck cancer. Bioengineering (Basel). 2023; 10:879. https://doi.org/10.3390/bioengineering10070879.

[77] Lara—Hernandez A, Rienmuller T, Juarez I, et al. Deep learning—based image registration in dynamic myocardial perfusion CT imaging. IEEE Trans Med Imaging. 2023; 42:684-696. https://doi.org/10.1109/TMI.2022.3214380.

[78] Wu L, Wang H, Chen Y, et al. Beyond radiologist—level liver lesion detection on multi—phase contrast—enhanced CT images by deep learning. iScience. 2023; 26:108183. https://doi.org/10.1016/j.isci.2023.108183.

[79] Mok TCW, Li Z, Bai Y, et al. Modality—Agnostic structural image representation learning for deformable multi—modality medical image registration. In: 2024 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR). 2024:11215-11225. https://doi.org/10.1109/CVPR52733.2024.01066.

[80] Xia TY, Zhou ZH, Meng XP, et al. Predicting microvascular invasion in hepatocellular carcinoma using CT—based radiomics model. Radiology. 2023; 307:e222729. https://doi.org/10.1148/radiol.222729.

[81] Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid—enhanced MR Imaging—correlation with molecular transporters and histopathologic features. Radiology. 2010; 256:817-826. https://doi.org/10.1148/radiol.10092214.

[82] Liu J, Wu J, Liu A, Bai Y, Zhang H, Yan M. Preoperative diagnosis of hepatocellular carcinoma patients with bile duct tumor thrombus using deep learning method. J China Univ Sci Technol. 2022; 52:6-11. https://doi.org/10.52396/JUSTC—2022—0057.

[83] Rhee H, Kim H, Park YN. Clinico—radio—pathological and molecular features of hepatocellular carcinomas with keratin 19 expression. Liver Cancer. 2020; 9:663-681. https://doi.org/10.1159/000510522.

[84] Wang W, Gu D, Wei J, et al. A radiomics—based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid—enhanced MRI. Eur Radiol. 2020; 30:3004-3014. https://doi.org/10.1007/s00330—019—06585—y.

[85] Yang F, Wan Y, Xu L, et al. MRI—Radiomics prediction for cytokeratin 19—positive hepatocellular carcinoma: a multicenter study. Front Oncol. 2021; 11:672126. https://doi.org/10.3389/fonc.2021.672126.

[86] Chen Y, Chen J, Zhang Y, et al. Preoperative prediction of cytokeratin 19 expression for hepatocellular carcinoma with deep learning radiomics based on gadoxetic acid—enhanced magnetic resonance imaging. J Hepatocell Carcinoma. 2021; 8:795-808. https://doi.org/10.2147/JHC.S313879.

[87] Hu X, Wang Q, Huang G, et al. Gadoxetic acid—enhanced MRI—based radiomics signature: a potential imaging biomarker for identifying cytokeratin 19—positive hepatocellular carcinoma. Comput Math Methods Med. 2023; 2023:5424204. https://doi.org/10.1155/2023/5424204.

[88] Jha D, Tomar NK, Biswas K, et al. CT liver segmentation via PVT—Based encoding and refined decoding. In: 2024 IEEE International Symposium on Biomedical Imaging (ISBI). 2024:1-5. https://doi.org/10.1109/ISBI56570.2024.10635659.

[89] Wang B, Rodriguez I, Breitinger L, et al. A Baseline for machine—learning—based Hepatocellular Carcinoma Diagnosis Using multi—modal Clinical Data. 2025. https://doi.org/10.48550/arXiv.2501.11535. ArXiv:2501.11535.

[90] Vally ZI, Khammissa RAG, Feller G, Ballyram R, Beetge M, Feller L. Errors in clinical diagnosis: a narrative review. J Int Med Res. 2023; 51:3000605231162798. https://doi.org/10.1177/03000605231162798.

[91] Singh H, Giardina TD, Meyer AN, Forjuoh SN, Reis MD, Thomas EJ. Types and origins of diagnostic errors in primary care settings. JAMA Intern Med. 2013; 173:418-425. https://doi.org/10.1001/jamainternmed.2013.2777.

[92] Bakrania A, Joshi N, Zhao X, Zheng G, Bhat M. Artificial intelligence in liver cancers: decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases. Pharmacol Res. 2023; 189:106706. https://doi.org/10.1016/j.phrs.2023.106706.

[93] Wang YY, Yang WX, Du QJ, Liu ZH, Lu MH, You CG. Construction and evaluation of a liver cancer risk prediction model based on machine learning. World J Gastrointest Oncol. 2024; 16:3839-3850. https://doi.org/10.4251/wjgo.v16.i9.3839.

[94] Si Y, Du J, Li Z, et al. Deep representation learning of patient data from Electronic Health Records (EHR): a systematic review. J Biomed Inform. 2021; 115:103671. https://doi.org/10.1016/j.jbi.2020.103671.

[95] Sun L, Yao HR, Gao G, Frieder O, Xiong C. Intercept Cancer: Cancer Pre—screening with Large Scale Healthcare Foundation Models. 2025. https://doi.org/10.48550/arXiv.2506.00209. ArXiv:2506.00209.

[96] Siebra C, Kurpicz—Briki M, Wac K. Transformers in health: a systematic review on architectures for longitudinal data analysis. Artif Intell Rev. 2024; 57:32. https://doi.org/10.1007/s10462—023—10677—z.

[97] Lim DK, Rashid NU, Oliva JB, Ibrahim JG. Unsupervised imputation of non—ignorably missing data using importance—weighted autoencoders. Stat Biopharm Res. 2025; 17:222-234. https://doi.org/10.1080/19466315.2024.2368787.

[98] Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014; 23:144-153. https://doi.org/10.1158/1055—9965.EPI—13—0870.

[99] Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD—2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016; 14:875-886 (e6). https://doi.org/10.1016/j.cgh.2015.12.042.

[100] Lin H, Li G, Delamarre A, et al. A liver stiffness—based etiology—independent machine learning algorithm to predict hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2024; 22:602-610 (e7). https://doi.org/10.1016/j.cgh.2023.11.005.

[101] Ren T, Hou X, Zhang X, et al. Validation of combined AFP, AFP—L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients. Heliyon. 2023; 9:e21906. https://doi.org/10.1016/j.heliyon.2023.e21906.

[102] Li Z, Lan L, Zhou Y, et al. Developing deep learning—based strategies to predict the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease from electronic health records. J Biomed Inform. 2024; 152:104626. https://doi.org/10.1016/j.jbi.2024.104626.

[103] Ma X, Huang L, Yu M, et al. Dynamic prediction of the risk of hepatocellular carcinoma after DAA treatment for hepatitis C patients. Cancer Control. 2025; 32:10732748251316609. https://doi.org/10.1177/10732748251316609.

[104] Arik S, Pfister T. Tabnet: Attentive Interpretable Tabular Learning. 2019. https://doi.org/10.48550/arXiv.1908.07442. ArXiv:1908.07442.

[105] Rockenschaub P, Akay EM, Carlisle BG, et al. External validation of AI—based scoring systems in the ICU: a systematic review and meta—analysis. BMC Med Inform Decis Mak. 2025; 25:5. https://doi.org/10.1186/s12911—024—02830—7.

[106] Yang J, Triendl H, Soltan AAS, Prakash M, Clifton DA. Addressing label noise for electronic health records: insights from computer vision for tabular data. BMC Med Inform Decis Mak. 2024; 24:183. https://doi.org/10.1186/s12911—024—02581—5.

[107] Jovic A, Frid N, Brkic K, Cifrek M. Interpretability and accuracy of machine learning algorithms for biomedical time series analysis — a scoping review. Biomed Signal Process Control. 2025; 110:108153. https://doi.org/10.1016/j.bspc.2025.108153.

[108] Cascarano A, Mur—Petit J, Hernandez—Gonzalez J, et al. Machine and deep learning for longitudinal biomedical data: a review of methods and applications. Artif Intell Rev. 2023; 56:1711-1771. https://doi.org/10.1007/s10462—023—10561—w.

[109] Fan Y, Zhang Z, Wang J. Research progress on electronic health records multimodal data fusion based on deep learning. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2024; 41:1062-1071. https://doi.org/10.7507/1001—5515.202310011.

[110] Hu J, Zhou ZY, Ran HL, Yuan XC, Zeng X, Zhang ZY. Diagnosis of liver tumors by multimodal ultrasound imaging. Medicine (Baltimore). 2020; 99:e21652. https://doi.org/10.1097/MD.0000000000021652.

[111] Huang W, Liu W, Zhang X, et al. LIDIA: precise liver tumor diagnosis on multi—phase contrast—enhanced CT via iterative fusion and asymmetric contrastive learning. In: Linguraru MG, Dou Q, Feragen A, et al., eds. Medical Image Computing and Computer Assisted Intervention, MICCAI 2024. Springer Science and Business Media Deutschland GmbH; 2024:394-404. https://doi.org/10.1007/978—3—031—72114—4_38.

[112] Hossain KF, Kamran SA, Ong J, Tavakkoli A. Enhancing efficient deep learning models with multimodal, multi—teacher insights for medical image segmentation. Sci Rep. 2025; 15:15948. https://doi.org/10.1038/s41598—025—91430—0.

[113] Huang B, Li H, Fujita H, et al. G—MBRMD: lightweight liver segmentation model based on guided teaching with multi—head boundary reconstruction mapping distillation. Comput Biol Med. 2024; 178:108733. https://doi.org/10.1016/j.compbiomed.2024.108733.

[114] Dantas PV, Sabino da Silva W, Cordeiro LC, Carvalho CB. A comprehensive review of model compression techniques in machine learning. Appl Intell. 2024; 54:11804-11844. https://doi.org/10.1007/s10489—024—05747—w.

[115] Murad MH, Vaa Stelling BE, West CP, et al. Measuring documentation burden in healthcare. J Gen Intern Med. 2024; 39:2837-2848. https://doi.org/10.1007/s11606—024—08956—8.

[116] Qi M, Qi M. Multidisciplinary Team (MDT)—based approaches for liver cancer treatment: a discussion paper on tumor boards and beyond. J Multidiscip Healthc. 2025; 18:7739-7748. https://doi.org/10.2147/JMDH.S566098.

[117] Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023; 616:259-265. https://doi.org/10.1038/s41586—023—05881—4.

[118] Mansi C, Ibrahim AM. From promise to proof: redesigning clinical workflows with generative AI. NEJM AI. 2025. https://doi.org/10.1056/AI—S2501083.

[119] Vladika J, Dhaini M, Matthes F. Facts Fade Fast: Evaluating Memorization of Outdated Medical Knowledge in Large Language Models. 2025. https://doi.org/10.48550/arXiv.2509.04304. ArXiv:2509.04304.

[120] Goodell AJ, Chu SN, Rouholiman D, Chu LF. Large language model agents can use tools to perform clinical calculations. NPJ Digit Med. 2025; 8:163. https://doi.org/10.1038/s41746—025—01475—8.

[121] Ke YH, Jin L, Elangovan K, et al. Retrieval augmented generation for 10 large language models and its generalizability in assessing medical fitness. NPJ Digit Med. 2025; 8:187. https://doi.org/10.1038/s41746—025—01519—z.

[122] Yeo YH, Samaan JS, Ng WH, et al. Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma. Clin Mol Hepatol. 2023; 29:721-732. https://doi.org/10.3350/cmh.2023.0089.

[123] Masthoff M, Zipser A, Praktiknjo M, et al. Performance of GPT—based large language models in hepatocellular carcinoma stratification: liver function assessment, BCLC staging, and treatment recommendations. Sci Rep. 2026; 16:18342. https://doi.org/10.1038/s41598—026—56992—7.

[124] Yang K, Lee J, Jang JW, Sung PS, Han JW. Evaluating the clinical utility of large language models for hepatocellular carcinoma treatment recommendations: a nationwide retrospective registry study. PLoS Med. 2026; 23:e1004855. https://doi.org/10.1371/journal.pmed.1004855.

[125] Wu K, Wu E, Wei K, et al. An automated framework for assessing how well LLMs cite relevant medical references. Nat Commun. 2025; 16:3615. https://doi.org/10.1038/s41467—025—58551—6.

[126] Nanua S, Steward R, Neely B, Datto M, Youens K. Retrieval—augmented generation for interpreting clinical laboratory regulations using large language models. J Pathol Inform. 2025; 19:100520. https://doi.org/10.1016/j.jpi.2025.100520.

[127] Savage T, Wang J, Gallo R, et al. Large language model uncertainty proxies: discrimination and calibration for medical diagnosis and treatment. J Am Med Inform Assoc. 2025; 32:139-149. https://doi.org/10.1093/jamia/ocae254.

[128] Yim WW, Denman T, Kwan SW, Yetisgen M. Tumor information extraction in radiology reports for hepatocellular carcinoma patients. AMIA Jt Summits Transl Sci Proc. 2016; 2016:455-464.

[129] Woznicki P, Laqua C, Fiku I, et al. Automatic structuring of radiology reports with on—premise open—source large language models. Eur Radiol. 2025; 35:2018-2029. https://doi.org/10.1007/s00330—024—11074—y.

[130] Liang JJ, Tsou CH, Dandala B, et al. Reducing physicians' cognitive load during chart review: a problem—oriented summary of the patient electronic record. AMIA Annu Symp Proc. 2022; 2021:763-772.

[131] Tam TYC, Sivarajkumar S, Kapoor S, et al. A framework for human evaluation of large language models in healthcare derived from literature review. NPJ Digit Med. 2024; 7:258. https://doi.org/10.1038/s41746—024—01258—7.

[132] Tzanis E, Adams LC, Akinci D'Antonoli T, et al. Agentic systems in radiology: principles, opportunities, privacy risks, regulation, and sustainability concerns. Diagn Interv Imaging. 2026; 107:7-16. https://doi.org/10.1016/j.diii.2025.10.002.

[133] Murillo PC, Lynch—Mejía MF, Quesada WR, et al. Real—world BCLC adherence and survival in hepatocellular carcinoma: first prospective study from Central America. Ann Hepatol. 2026; 31:102154. https://doi.org/10.1016/j.aohep.2025.102154.

[134] Nelles C, Wagner A, Lennartz S, et al. Clinical benefit of structured reporting using the Liver Imaging Reporting and Data System (LI—RADS) in MRI in patients at risk for hepatocellular carcinoma. [Klinischer Nutzen der strukturierten Befundung mittels des Liver Imaging Reporting and Data System (LI—RADS) in der MRT bei Patienten mit erhohtem Risiko fur ein hepatozellulares Karzinom]. RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren. 2026; 198:209-218. https://doi.org/10.1055/a—2553—1392.

[135] Bluethgen C, Van Veen D, Truhn D, et al. Agentic Systems in Radiology: Design, Applications, Evaluation, and Challenges. 2025. https://doi.org/10.48550/arXiv.2510.09404. ArXiv:2510.09404.

[136] Madrid—García A, Benavent D, Merino—Barbancho B. From chat to act: large language model agents and agentic AI as the next frontier of AI in rheumatology. EULAR Rheumatol Open. 2025; 1:147-156. https://doi.org/10.1016/j.ero.2025.06.012.

[137] Chitoran E, Rotaru V, Gelal A, et al. Using artificial intelligence to develop clinical decision support systems—the evolving road of personalized oncologic therapy. Diagnostics (Basel). 2025; 15:2391. https://doi.org/10.3390/diagnostics15182391.

[138] Salehi S, Singh Y, Horst KK, Hathaway QA, Erickson BJ. Agentic AI and large language models in radiology: opportunities and hallucination challenges. Bioengineering (Basel). 2025; 12:1303. https://doi.org/10.3390/bioengineering12121303.

[139] Wind S, Sopa J, Truhn D, et al. Multi—step retrieval and reasoning improves radiology question answering with large language models. NPJ Digit Med. 2025; 8:790. https://doi.org/10.1038/s41746—025—02250—5.

[140] Wang L, Tian F, Li C, et al. A multimodal LLM—agent framework for personalized clinical decision—making in hepatocellular carcinoma. Patterns (N Y). 2025; 6:101364. https://doi.org/10.1016/j.patter.2025.101364.

[141] Nam Y, Kim DY, Kyung S, et al. Multimodal large language models in medical imaging: current state and future directions. Korean J Radiol. 2025; 26:900-923. https://doi.org/10.3348/kjr.2025.0599.

[142] Yao H, Zhang R, Huang J, et al. A Survey on Agentic Multimodal Large Language Models. 2025. https://doi.org/10.48550/arXiv.2510.10991. ArXiv:2510.10991.

[143] Ayaz M, Pasha MF, Alahmadi TJ, Abdullah NNB, Alkahtani HK. Transforming healthcare analytics with FHIR: a framework for standardizing and analyzing clinical data. Healthcare (Basel). 2023; 11:1729. https://doi.org/10.3390/healthcare11121729.

[144] Gallifant J, Kellogg K, Butler M, et al. A Field Guide to Deploying AI Agents in Clinical Practice. 2025. https://doi.org/10.48550/arXiv.2509.26153. ArXiv:2509.26153.

[145] Xu Y, Wang Y, Zhou F, et al. A multimodal knowledge—enhanced whole—slide pathology foundation model. Nat Commun. 2025; 16:11406. https://doi.org/10.1038/s41467—025—66220—x.

[146] Gong Z, Du M, Li Y, et al. Machine learning identifies TIME subtypes linking EGFR mutations and immune states in lung adenocarcinoma. NPJ Digit Med. 2025; 8:796. https://doi.org/10.1038/s41746—025—02172—2.

[147] Park H, Youm C, Cheon SM, et al. Using machine learning to identify Parkinson's disease severity subtypes with multimodal data. J Neuroeng Rehabil. 2025; 22:126. https://doi.org/10.1186/s12984—025—01648—2.

[148] Xian S, Grabowska ME, Kullo IJ, et al. Transformer patient embedding using electronic health records enables patient stratification and progression analysis. NPJ Digit Med. 2025; 8:521. https://doi.org/10.1038/s41746—025—01872—z.

[149] Valan B, Prakash A, Ratliff W, et al. Evaluating sepsis watch generalizability through multisite external validation of a sepsis machine learning model. NPJ Digit Med. 2025; 8:350. https://doi.org/10.1038/s41746—025—01664—5.

[150] Giulianotti PC, Bianco FM, Daskalaki D, Gonzalez—Ciccarelli LF, Kim J, Benedetti E. Robotic liver surgery: technical aspects and review of the literature. Hepatobiliary Surg Nutr. 2016; 5:311-321. https://doi.org/10.21037/hbsn.2015.10.05.

[151] Liu R, Abu Hilal M, Wakabayashi G, et al. International experts consensus guidelines on robotic liver resection in 2023. World J Gastroenterol. 2023; 29:4815-4830. https://doi.org/10.3748/wjg.v29.i32.4815.

[152] Spiegelberg J, Iken T, Diener MK, Fichtner—Feigl S. Robotic—assisted surgery for primary hepatobiliary tumors—possibilities and limitations. Cancers (Basel). 2022; 14:265. https://doi.org/10.3390/cancers14020265.

[153] Preston WA, Spitofsky NR, Bodzin AS. A contemporary review of robotic resection for hepatocellular carcinoma. Cancers (Basel). 2024; 16:3806. https://doi.org/10.3390/cancers16223806.

[154] Moglia A, Georgiou K, Georgiou E, Satava RM, Cuschieri A. A systematic review on artificial intelligence in robot—assisted surgery. Int J Surg. 2021; 95:106151. https://doi.org/10.1016/j.ijsu.2021.106151.

[155] Maier—Hein L, Eisenmann M, Sarikaya D, et al. Surgical data science — from concepts toward clinical translation. Med Image Anal. 2022; 76:102306. https://doi.org/10.1016/j.media.2021.102306.

[156] Golse N, Petit A, Lewin M, Vibert E, Cotin S. Augmented reality during open liver surgery using a markerless non—rigid registration system. J Gastrointest Surg. 2021; 25:662-671. https://doi.org/10.1007/s11605—020—04519—4.

[157] Nakano Y, Uematsu Y, Abe Y, et al. Artificial intelligence—enhanced navigation for early detection of inferior vena cava and root of the major hepatic veins during robotic hepatectomy. J Hepatobiliary Pancreat Sci. 2025; 32:721-723. https://doi.org/10.1002/jhbp.12195.

[158] de Franchis R, Bosch J, Garcia—Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII — renewing consensus in portal hypertension. J Hepatol. 2022; 76:959-974. https://doi.org/10.1016/j.jhep.2021.12.022.

[159] Cocca S, Carloni L, Marocchi M, et al. Post—trans—arterial chemoembolization hepatic necrosis and biliary stenosis: clinical characteristics and endoscopic approach. World J Clin Cases. 2023; 11:8434-8439. https://doi.org/10.12998/wjcc.v11.i36.8434.

[160] Kohli DR, Amateau SK, Desai M, et al. American Society for Gastrointestinal Endoscopy guideline on management of post—liver transplant biliary strictures: summary and recommendations. Gastrointest Endosc. 2023; 97:607-614. https://doi.org/10.1016/j.gie.2022.10.007.

[161] Boskoski I, Orlandini B, Papparella LG, et al. Robotics and artificial intelligence in gastrointestinal endoscopy: updated review of the literature and state of the art. Current Robotics Reports. 2021; 2:43-54. https://doi.org/10.1007/s43154—020—00040—3.

[162] Tada N, Sumiyama K. Robotic platforms for therapeutic flexible endoscopy: a literature review. Diagnostics (Basel). 2024; 14:595. https://doi.org/10.3390/diagnostics14060595.

[163] Berzin TM, Parasa S, Wallace MB, Gross SA, Repici A, Sharma P. Position statement on priorities for artificial intelligence in GI endoscopy: a report by the ASGE Task Force. Gastrointest Endosc. 2020; 92:951-959. https://doi.org/10.1016/j.gie.2020.06.035.

[164] Pannala R, Krishnan K, Melson J, et al. Artificial intelligence in gastrointestinal endoscopy. VideoGIE. 2020; 5:598-613. https://doi.org/10.1016/j.vgie.2020.08.013.

[165] Chadebecq F, Lovat LB, Stoyanov D. Artificial intelligence and automation in endoscopy and surgery. Nat Rev Gastroenterol Hepatol. 2023; 20:171-182. https://doi.org/10.1038/s41575—022—00701—y.

[166] Yan B, Yang Y, Peng L, et al. Robotic—assisted bile duct cannulation during endoscopic retrograde cholangiopancreatography: a randomised controlled crossover animal study. Int J Med Robot. 2026; 22:e70174. https://doi.org/10.1002/rcs.70174.

[167] Thirunavukarasu AJ, Hu ML, Foster WP, Xue K, Cehajic—Kapetanovic J, MacLaren RE. Robot—assisted eye surgery: a systematic review of effectiveness, safety, and practicality in clinical settings. Transl Vis Sci Technol. 2024; 13:20. https://doi.org/10.1167/tvst.13.6.20.

[168] Panettieri E, Campisi A, Bianchi V, Giuliante F, Rose AMD. Artificial intelligence and its role in guiding liver—directed therapy for hepatocellular carcinoma: is it ready for prime time? Hepatoma Res. 2022; 8:41. https://doi.org/10.20517/2394—5079.2022.57.

[169] Zhang J, Fang J, Xu Y, Si G. How AI and robotics will advance interventional radiology: narrative review and future perspectives. Diagnostics (Basel). 2024; 14:1393. https://doi.org/10.3390/diagnostics14131393.

[170] Lamata P, Ali W, Cano A, et al. Augmented Reality for Minimally Invasive Surgery: Overview and Some Recent Advances. IntechOpen; 2010. https://doi.org/10.5772/7128.

[171] Ricciardo G, Garufi G, Scalia G, et al. Enhancing palliative care in vulnerable patients: robot—assisted radiofrequency ablation for multiple spinal metastases — technical insights and preliminary outcomes. J Craniovertebral Junction Spine. 2024; 15:166-172. https://doi.org/10.4103/jcvjs.jcvjs_175_23.

[172] Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019; 17:195. https://doi.org/10.1186/s12916—019—1426—2.

[173] Zhang L, Wang X, Yang D, et al. Generalizing deep learning for medical image segmentation to unseen domains via deep stacked transformation. IEEE Trans Med Imaging. 2020; 39:2531-2540. https://doi.org/10.1109/TMI.2020.2973595.

[174] Tiyarattanachai T, Apiparakoon T, Marukatat S, et al. Development and validation of artificial intelligence to detect and diagnose liver lesions from ultrasound images. PLoS One. 2021; 16:e0252882. https://doi.org/10.1371/journal.pone.0252882.

[175] Ciocalteu A, Urhut CM, Streba CT, Kamal A, Mamuleanu M, Sandulescu LD. Artificial intelligence in contrast enhanced ultrasound: a new era for liver lesion assessment. World J Gastroenterol. 2025; 31:112196. https://doi.org/10.3748/wjg.v31.i42.112196.

[176] Fatima A, Shafique MA, Alam K, Fadlalla Ahmed TK, Mustafa MS. ChatGPT in medicine: a cross—disciplinary systematic review of chatgpt's (artificial intelligence) role in research, clinical practice, education, and patient interaction. Medicine (Baltimore). 2024; 103:e39250. https://doi.org/10.1097/MD.0000000000039250.

[177] Alansari A, Luqman H. Large Language Models Hallucination: A Comprehensive Survey. 2025. https://doi.org/10.48550/arXiv.2510.06265. ArXiv:2510.06265.

[178] Sarker A, Zhang R, Wang Y, et al. Natural language processing for digital health in the era of large language models. Yearb Med Inform. 2024; 33:229-240. https://doi.org/10.1055/s—0044—1800750.

[179] Pesaranghader A, Li E. Hallucination Detection and Mitigation in Large Language Models. 2026. https://doi.org/10.48550/arXiv.2601.09929. ArXiv:2601.09929.

[180] Kostick—Quenet KM, Gerke S. AI in the hands of imperfect users. NPJ Digit Med. 2022; 5:197. https://doi.org/10.1038/s41746—022—00737—z.

[181] Goddard K, Roudsari A, Wyatt JC. Automation bias: a systematic review of frequency, effect mediators, and mitigators. J Am Med Inform Assoc. 2012; 19:121-127. https://doi.org/10.1136/amiajnl—2011—000089.

[182] Liu F, Niu Y, Zhang Q, et al. A foundational architecture for AI agents in healthcare. Cell Rep Med. 2025; 6:102374. https://doi.org/10.1016/j.xcrm.2025.102374.

[183] Selvan R, Schon J, Dam EB. Operating critical machine learning models in resource constrained regimes. In: Medical Image Computing and Computer Assisted Intervention — MICCAI 2023 Workshops. Vol. 14394 of Lecture Notes in Computer Science. Springer; 2024:325-335. https://doi.org/10.1007/978—3—031—47425—5_29.

[184] Chowdhery A, Narang S, Devlin J, et al. PaLM: scaling language modeling with pathways. J Mach Learn Res. 2023; 24:1-113. https://www.jmlr.org/papers/v24/22—1144.html.

[185] Liu HI, Galindo M, Xie HX, et al. Lightweight deep learning for resource—constrained environments: a survey. ACM Comput Surv. 2024; 56:267. https://doi.org/10.1145/3657282.

[186] Alam S, Yakopcic C, Wu Q, Barnell M, Khan S, Taha TM. Survey of deep learning accelerators for edge and emerging computing. Electronics. 2024; 13:2988. https://doi.org/10.3390/electronics13152988.

[187] Houssein EH, Gamal AM, Younis EMG, Mohamed E. Explainable artificial intelligence for medical imaging systems using deep learning: a comprehensive review. Clust Comput. 2025; 28:469. https://doi.org/10.1007/s10586—025—05281—5.

[188] Kruschel S, Hambauer N, Weinzierl S, Zilker S, Kraus M, Zschech P. Challenging the performance—interpretability trade—off: an evaluation of interpretable machine learning models. Bus Inf Syst Eng. 2026; 68:159-183. https://doi.org/10.1007/s12599—024—00922—2.

[189] Soenksen LR, Ma Y, Zeng C, et al. Integrated multimodal artificial intelligence framework for healthcare applications. NPJ Digit Med. 2022; 5:149. https://doi.org/10.1038/s41746—022—00689—4.

[190] Sauerbrei A, Kerasidou A, Lucivero F, Hallowell N. The impact of artificial intelligence on the person—centred, doctor—patient relationship: some problems and solutions. BMC Med Inform Decis Mak. 2023; 23:73. https://doi.org/10.1186/s12911—023—02162—y.

[191] Chen S, Kann BH, Foote MB, et al. Use of artificial intelligence chatbots for cancer treatment information. JAMA Oncol. 2023; 9:1459-1462. https://doi.org/10.1001/jamaoncol.2023.2954.

[192] Worms MA, Burns D, Paskow M, et al. Patient experience of hepatocellular carcinoma and their treatment goals: an international qualitative study and patient journey map. Adv Ther. 2024; 41:3598-3614. https://doi.org/10.1007/s12325—024—02939—1.

[193] Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete—choice experiment. Cancers (Basel). 2023; 15:1470. https://doi.org/10.3390/cancers15051470.

[194] Richardson JP, Smith C, Curtis S, et al. Patient apprehensions about the use of artificial intelligence in healthcare. NPJ Digit Med. 2021; 4:140. https://doi.org/10.1038/s41746—021—00509—1.

[195] Robertson C, Woods A, Bergstrand K, Findley J, Balser C, Slepian MJ. Diverse patients' attitudes towards Artificial Intelligence (AI) in diagnosis. PLOS Digit Health. 2023; 2:e0000237. https://doi.org/10.1371/journal.pdig.0000237.

[196] Hilbers D, Nekain N, Bates A, Nunez JJ. Patient attitudes toward artificial intelligence in cancer care: scoping review. JMIR Cancer. 2025; 11:e74010. https://doi.org/10.2196/74010.

[197] Hassan N, Slight R, Bimpong K, et al. Systematic review to understand users perspectives on AI—enabled decision aids to inform shared decision making. NPJ Digit Med. 2024; 7:332. https://doi.org/10.1038/s41746—024—01326—y.

[198] Mello MM, Char D, Xu SH. Ethical obligations to inform patients about use of AI tools. JAMA. 2025; 334:767-770. https://doi.org/10.1001/jama.2025.11417.

[199] Mello MM, Guha N. Understanding liability risk from using health care artificial intelligence tools. N Engl J Med. 2024; 390:271-278. https://doi.org/10.1056/NEJMhle2308901.

[200] Shah SM, Khan RA. Secondary use of electronic health record: opportunities and challenges. IEEE Access. 2020; 8:136947-136965. https://doi.org/10.1109/ACCESS.2020.3011099.

[201] Venkatesaramani R, Malin BA, Vorobeychik Y. Re—identification of individuals in genomic datasets using public face images. Sci Adv. 2021; 7:eabg3296. https://doi.org/10.1126/sciadv.abg3296.

[202] Kasyap H, Tripathy S. Privacy—preserving decentralized learning framework for healthcare system. ACM Trans Multimed Comput Commun Appl. 2021; 17:68. https://doi.org/10.1145/3426474.

[203] Chinta SV, Wang Z, Palikhe A, et al. AI—driven healthcare: fairness in AI healthcare: a survey. PLOS Digit Health. 2025; 4:e0000864. https://doi.org/10.1371/journal.pdig.0000864.

[204] Pantanowitz L, Hanna M, Pantanowitz J, et al. Regulatory aspects of artificial intelligence and machine learning. Mod Pathol. 2024; 37:100609. https://doi.org/10.1016/j.modpat.2024.100609.

[205] Feng J, Phillips RV, Malenica I, et al. Clinical artificial intelligence quality improvement: towards continual monitoring and updating of AI algorithms in healthcare. NPJ Digit Med. 2022; 5:66. https://doi.org/10.1038/s41746—022—00611—y.

[206] Vasey B, Nagendran M, Campbell B, et al. Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE—AI. BMJ. 2022; 377:e070904. https://doi.org/10.1136/bmj—2022—070904.

[207] Shaw J, Rudzicz F, Jamieson T, Goldfarb A. Artificial intelligence and the implementation challenge. J Med Internet Res. 2019; 21:e13659. https://doi.org/10.2196/13659.

[208] Coiera E. The last mile: where artificial intelligence meets reality. J Med Internet Res. 2019; 21:e16323. https://doi.org/10.2196/16323.

[209] Juluru K, Shih HH, Keshava Murthy KN, et al. Integrating AI algorithms into the clinical workflow. Radiol Artif Intell. 2021; 3:e210013. https://doi.org/10.1148/ryai.2021210013.

[210] Agarwal PD, Phillips P, Hillman L, et al. Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival. J Clin Gastroenterol. 2017; 51:845-849. https://doi.org/10.1097/MCG.0000000000000825.

[211] Singal AG, Tiro JA, Murphy CC, et al. Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial. Hepatology. 2019; 69:121-130. https://doi.org/10.1002/hep.30129.

[212] Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta—analysis. Hepatology. 2021; 73:713-725. https://doi.org/10.1002/hep.31309.

[213] Nazareth S, Leembruggen N, Tuma R, et al. Nurse—led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis. Int J Nurs Pract. 2016; 22(Suppl 2):3-11. https://doi.org/10.1111/ijn.12472.

[214] Sendak MP, Ratliff W, Sarro D, et al. Real—world integration of a sepsis deep learning technology into routine clinical care: implementation study. JMIR Med Inform. 2020; 8:e15182. https://doi.org/10.2196/15182.